What is William Blair’s Forecast for Repligen Q1 Earnings?

Repligen Co. (NASDAQ:RGEN) – Analysts at William Blair dropped their Q1 2025 earnings per share (EPS) estimates for shares of Repligen in a research note issued to investors on Friday, February 21st. William Blair analyst M. Larew now forecasts that the biotechnology company will post earnings per share of $0.33 for the quarter, down from their previous forecast of $0.38. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. William Blair also issued estimates for Repligen’s Q2 2025 earnings at $0.45 EPS, Q3 2025 earnings at $0.44 EPS, Q4 2025 earnings at $0.48 EPS, FY2025 earnings at $1.71 EPS, Q1 2026 earnings at $0.48 EPS, Q2 2026 earnings at $0.59 EPS, Q3 2026 earnings at $0.58 EPS, Q4 2026 earnings at $0.64 EPS and FY2026 earnings at $2.28 EPS.

Other equities analysts have also issued research reports about the company. StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. Canaccord Genuity Group increased their target price on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday, February 21st. Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $180.00 target price on shares of Repligen in a research note on Friday, February 21st. Finally, TD Cowen assumed coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $181.00.

Repligen Trading Down 2.0 %

Shares of RGEN opened at $161.47 on Monday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a 12-month low of $113.50 and a 12-month high of $203.13. The firm has a market capitalization of $9.05 billion, a PE ratio of -316.61, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. The stock’s fifty day simple moving average is $155.30 and its 200-day simple moving average is $148.57.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million.

Hedge Funds Weigh In On Repligen

A number of large investors have recently bought and sold shares of RGEN. Champlain Investment Partners LLC increased its position in shares of Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after acquiring an additional 850,345 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Repligen by 11.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock valued at $1,027,165,000 after buying an additional 743,815 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in shares of Repligen by 183.1% in the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock valued at $132,227,000 after buying an additional 594,189 shares during the last quarter. Groupama Asset Managment boosted its holdings in shares of Repligen by 12,321.0% in the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company’s stock valued at $58,142,000 after buying an additional 400,680 shares during the last quarter. Finally, Alyeska Investment Group L.P. acquired a new stake in Repligen during the 4th quarter valued at $53,428,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.